Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PRTO vs TENX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TENX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–1 Matrix Metrics)

TENX Overall Winner 6-Pillar Tally: PRTO 2 – 3 TENX (1 Tie) Matrix Metrics: PRTO 1 – 8 TENX

As of Nov 20, 2026, Tenax Therapeutics, Inc. (TENX) is the stronger overall head-to-head candidate over PRTO (PRTO) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PRTO carries a Unified Composite Score of 33.3/100 (SELL) at $24.45 (N/M Forward P/E, N/A operating margin), whereas TENX carries 45.5/100 (HOLD) at $1.25 (0.3x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: PRTO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.6); meanwhile TENX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PRTO vs TENX
PRTO US Equity
PRTO
Institutional Equity
$24.45
-3.36% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.89β · 21% Vol
Unified Composite Score
33.3 / 100 SELL
Tech 12.0 Fund 36.0 Flow 50.0 Mom 34.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.3%), weak momentum, RSI 23
RSI-14: 22.6 · SMA20: $26.61 · SMA50: $27.03
TENX NASDAQ Head-to-Head Winner
Tenax Therapeutics, Inc.
Pharmaceutical Preparations
$1.25
-10.07% 1D
Market Cap $63.3M
TTM Revenue N/A
Forward P/E 0.3x
Beta / 30D Vol 1.42β · 75% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 57.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.8%), weak momentum, RSI 30
RSI-14: 29.5 · SMA20: $1.65 · SMA50: $1.74

6-Pillar Scorecard Institutional Category Breakdown (PRTO 2 – 3 TENX)

Columns: Metric · PRTO · TENX
1. Valuation Multiples TENX
Forward P/E N/M 0.3x
Trailing P/E N/M 0.3x
PEG Ratio N/M 1.44x
EV / Revenue N/M N/M
2. Growth & Scale TENX
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $63.3M
3. Profitability & Quality TENX
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -64.2%
4. Balance Sheet & Cash Flow PRTO
Cash Generation (TTM) N/A -$49M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $2.03 Book/Sh · -64.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRTO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 148.9% (24th %ile)
Put/Call OI Skew N/A 0.08x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PRTO (1) vs TENX (8)
Institutional Metric PRTO TENX Criterion Row Edge
Market Capitalization
Scale
N/A $63.3M Larger Scale TENX
Trailing P/E Ratio
Valuation
N/M 0.3x Lower Multiple TENX
Forward P/E Ratio
Valuation
N/M 0.3x Lower Multiple TENX
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth TENX
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin TENX
Net Profit Margin
Profitability
N/A 0.0% Higher Margin TENX
Return on Equity (ROE)
Capital Efficiency
N/A -64.2% Higher ROE TENX
52-Week Range Position
Momentum
0% ($24–$29) 0% ($1–$19) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
0.89β · 21% Vol 1.42β · 75% Vol Lower Realized Risk PRTO
Unified Institutional Score
Composite Signal
33.3 / 100 (SELL) 45.5 / 100 (HOLD) Higher Composite TENX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.44x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$49M ($2.03 Book/Sh · -64.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRTO +19.42 pp
PRTO: -9.56% · TENX: -28.98%
3M Horizon PRTO +14.26 pp
PRTO: -14.31% · TENX: -28.57%
6M Horizon PRTO +78.48 pp
PRTO: -11.41% · TENX: -89.89%
1Y Horizon PRTO +87.68 pp
PRTO: -3.39% · TENX: -91.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRTO vs TENX. Trailing 12-month operating profitability (PRTO N/A vs TENX 0.0%) and valuation multiples (PRTO N/M vs TENX 0.3x Forward P/E) are benchmarked directly in Pillar 4 below.

PRTO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
TENX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.2% · 0.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PRTO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PRTO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TENX BREAKDOWN
95d in phase · OBV DISTRIBUTION
Current IV 148.9%
IV Percentile 24th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TENX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PRTO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TENX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $63.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PRTO vs TENX Key Questions & Quantitative Answers

As of Nov 20, 2026, Tenax Therapeutics, Inc. (TENX) is the stronger overall head-to-head candidate over PRTO (PRTO) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PRTO carries a Unified Composite Score of 33.3/100 (SELL) at $24.45 (N/M Forward P/E, N/A operating margin), whereas TENX carries 45.5/100 (HOLD) at $1.25 (0.3x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PRTO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.6); meanwhile TENX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TENX leads the Growth & Scale pillar: PRTO posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with TENX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PRTO generates N/A in USD-normalized revenue versus N/A for TENX. In operating R&D and SG&A reinvestment, PRTO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TENX.

TENX screens cheaper on headline valuation multiples. PRTO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas TENX trades at 0.3x Forward P/E, 0.3x Trailing P/E, 1.44x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRTO (N/A ROE) versus TENX (-64.2% ROE) capital efficiency.

In options market volatility and institutional positioning, PRTO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.89β · 21% Vol realized risk). By comparison, TENX carries 148.9% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.